Pharmaceutical

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Key Manufacturing Milestone Strengthens PolyPid’s Position as it Advances Towards Global Commercialization of D-PLEX₁₀₀ Following Successful SHIELD II Phase 3…

3 months ago

TOMI Environmental Solutions to Participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16–17, 2025

FREDERICK, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in…

3 months ago

TOMI Environmental Solutions to Participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16–17, 2025

FREDERICK, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in…

3 months ago

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

Strategic capital deployment advances Company’s blockchain treasury model and biopharma development initiatives SARASOTA, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Silo…

3 months ago

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

Strategic capital deployment advances Company’s blockchain treasury model and biopharma development initiatives SARASOTA, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Silo…

3 months ago

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing…

3 months ago

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing…

3 months ago

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of…

3 months ago

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of…

3 months ago

SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial

Anand Sundaram Vice President, Head of Commercial, SpyGlass Pharma ALISO VIEJO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma,…

3 months ago